Werner Anja, Schäfer Simon, Zaytseva Olga, Albert Heike, Lux Anja, Krištić Jasminka, Pezer Marija, Lauc Gordan, Winkler Thomas, Nimmerjahn Falk
Chair of Genetics, Department of Biology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erwin-Rommelstr. 3, 91058 Erlangen, Germany.
Genos Ltd, Glycoscience Research Laboratory, Borongajska 83H, 10000 Zagreb, Croatia.
iScience. 2021 Sep 1;24(9):103076. doi: 10.1016/j.isci.2021.103076. eCollection 2021 Sep 24.
Systemic lupus erythematosus (SLE) is characterized by a loss of self-tolerance, systemic inflammation, and multi-organ damage. While a variety of therapeutic interventions are available, it has become clear that an early diagnosis and treatment may be key to achieve long lasting therapeutic responses and to limit irreversible organ damage. Loss of humoral tolerance including the appearance of self-reactive antibodies can be detected years before the actual onset of the clinical autoimmune disease, representing a potential early point of intervention. Not much is known, however, about how and to what extent this pre-phase of disease impacts the onset and development of subsequent autoimmunity. By targeting the B cell compartment in the pre-disease phase of a spontaneous mouse model of SLE we now show, that resetting the humoral immune system during the clinically unapparent phase of the disease globally alters immune homeostasis delaying the downstream development of systemic autoimmunity.
Immunol Res. 2003
Methods Mol Biol. 2014
Front Immunol. 2020
J Autoimmun. 2020-6
J Immunoassay Immunochem. 2017
J Autoimmun. 2016-7-6
Ann Ital Chir. 2014
Front Immunol. 2019-7-10
Semin Immunol. 2019-11-1
Front Immunol. 2019-3-19
Annu Rev Cell Dev Biol. 2019-3-18
J Am Soc Nephrol. 2018-1-11